MAINZ BIOMED N.V. 8-K

What Happened

• MAINZ BIOMED N.V. (MYNZ) filed a Form 8‑K on March 17, 2026 reporting it received a pre‑payment of the subscription amount for the second tranche of a previously announced private placement. The related Securities Purchase Agreement is with David E. Lazar and is dated February 13, 2026. The company says the closing of the second tranche is expected after required stockholder approvals and prior to April 2026, subject to customary closing conditions.
• The filing also included a Regulation FD disclosure: a press release dated March 17, 2026 (Exhibit 99.1) regarding strategy and acquisition targets by an entity doing business as Quantum Cyber.

Key Details

• Pre‑payment received: March 17, 2026 (amount not disclosed in the 8‑K).
• Purchase agreement counterparty: David E. Lazar (Securities Purchase Agreement dated February 13, 2026).
• Expected closing window: After stockholder approvals and before April 2026, contingent on customary closing conditions.
• Exhibit filed: Press release dated March 17, 2026 (Exhibit 99.1) — furnished under Regulation FD.

Why It Matters

• For investors, the pre‑payment signals progress toward completing the second tranche of the private placement, which can provide near‑term financing if the closing occurs as expected.
• However, the closing is conditional on shareholder approvals and other customary conditions; the company explicitly warns these timing and completion matters could change. The 8‑K did not disclose the dollar amount of the pre‑payment or full use of proceeds in this filing, so investors should watch for future disclosures (e.g., proxy statements, closing notices, or amended filings) for amounts and how funds will be used.